Pfizer is to make its breast cancer drug Ibrance (palbociclib) available for free to NHS patients while it waits for a final decision on the drug’s cost-effectiveness. The drug has been hailed ...

The cost-effectiveness agency has said that Ibrance (palbociclib) plus fulvestrant can be used routinely on the NHS as a second-line therapy for patients with advanced hormone receptor-positive ...

The NDA is seeking approval for inavolisib in combination with Pfizer’s PFE Ibrance (palbociclib) and AstraZeneca’s AZN Faslodex (fulvestrant) to treat adult patients with PIK3CA-mutated ...

Among patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer, treatment with Itovebi (inavolisib) plus Ibrance (palbociclib) and ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and antibody-drug conjugate franchises alongside potential financial impacts ...

Further results from the randomised, double-blind trial (NCT04191499) showed that Itovebi, otherwise known as inavolisib, when used in combination with Ibrance (palbociclib) and Faslodex ...

in combination with palbociclib (Ibrance ®) and fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine ...

The phase INAVO120 trial has been evaluating the drug in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and AstraZeneca’s hormone therapy Faslodex (fulvestrant) in patient with ...